Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ra-223 in Asian patients with symptomatic CRPC with bone metastases
CTR20131688Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 3 trial of radium-223 dichloride in prostate cancer (PCa), sponsored by Bayer. Started Apr 2014; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20131688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131688.